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ABSTRACT 
The pathophysiology of acute coronary syndromes (ACS) includes atherosclerotic plaque 
rupture and coronary thrombus formation. Antithrombotic treatment is effective but recurrent 
atherothrombotic or bleeding complications are not uncommon.  
Aim: To study new markers and methods concerning haemostasis in ACS and conditions 
associated with high risk of this disease, in the search for laboratory tools that could help increase 
understanding of disease mechanisms and help to identify patients at risk.  
Methods and Results: Eighty-seven patients suffering from ACS were investigated at 
admission (S1), after 24 h on standard antithrombotic treatment (S2), and six months after the 
acute event (S3). Sex- and age-matched healthy controls were also investigated. Thrombin 
generation in vivo was assessed by measurement of prothrombin fragment F1+2 in plasma and in 
vitro by using the calibrated automated thrombogram (CAT). Fibrinolysis was measured by 
assessment of PAI-1 and TAFI activity concentrations. The latter method was used as a result of a 
methods evaluation study. We also employed a global method developed by our group (Oh-
index), to evaluate haemostasis. Oh-index gives a measure of fibrin formation and degradation 
capacity in plasma. Furthermore, a flow cytometric assay set up by our group was employed to 
measure platelet microparticles (PMP) in plasma formed upon platelet activation. In addition, we 
investigated ADAMTS13, an enzyme previously called von Willebrand factor (VWF)-degrading 
protease, and we also measured its substrate (i.e. VWF). The ACS patients, of whom more than 
half were high-risk patients (TIMI score ≥ 4), showed signs of inflammation and endothelial 
activation, as expected. Only the CAT method could detect hypercoagulability in the patients 
(increased peak thrombin concentration) and this finding was evident acutely and 6 months after 
the event. Thrombin generation in vivo (F1+2) or fibrin generation capacity in plasma did not 
indicate hypercoagulability at any time point. CAT, F1+2 and fibrin generation capacity were 
strongly reduced following initiation of antithrombotic treatment (S2), as expected. PAI-1 and 
TAFI levels were elevated, reflecting impaired fibrinolysis, but this was not observed with our 
method that assesses fibrin degradation capacity; rather, this method indicated increased 
fibrinolytic capacity at admission and this capacity was grossly increased after initiation of 
standard antithrombotic treatment (S2). ADAMTS13 activity and antigen concentrations were 
unchanged during and after ACS, but the VWF:ADAMTS13 ratio was significantly elevated in 
ACS patients and two different populations of patients with diabetes mellitus. The ACS patients 
had significantly elevated concentrations of PMP at admission, particularly PMP subpopulations 
with exposed P-selectin and tissue factor (TF). Concentrations of PMP decreased following 
initiation of antithrombotic treatment (S2), but in the subpopulations with exposed P-selectin and 
TF they remained significantly higher than in controls at 6 months (S3). 
Conclusions: Our PMP data are in agreement with the concept of a dominating role of 
platelets in the pathophysiology of ACS, and PMP deserve to be studied in more detail in 
coronary artery disease, including their roles in the effects of treatment and relationships to 
coagulation, risk and prognosis. However, the data on coagulation and fibrinolysis obtained in this 
study indicate that there is not yet sufficient information to support the clinical use of markers to 
assess coagulation or fibrinolysis in individual patients. 
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